Skip to main content

Table 1 Echocardiographic parameters

From: The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity

Echo variable Treatment arm Group Baseline Week 13 p
   TRZ 717 ± 12 729 ± 10 0.62
  Placebo DOX 725 ± 10 701 ± 18 0.58
   DOX+ TRZ 690 ± 14 695 ± 18 0.82
Heart Rate (bpm)   TRZ 735 ± 15 740 ± 12 0.88
  Aliskiren DOX 705 ± 14 701 ± 21 0.72
   DOX+ TRZ 705 ± 14 701 ± 21 0.72
   TRZ 705 ± 18 710 ± 12 0.9
  Perindopril DOX 722 ± 14 720 ± 18 0.77
   DOX+ TRZ 722 ± 14 720 ± 18 0.77
   TRZ 744 ± 13 735 ± 12 0.67
  Valsartan DOX 695 ± 14 705 ± 12 0.72
   DOX+ TRZ 695 ± 14 705 ± 12 0.72
   TRZ 0.82 ± 0.02 0.84 ± 0.01 0.92
  Placebo DOX 0.83 ± 0.02 0.81 ± 0.01 0.97
   DOX+ TRZ 0.84 ± 0.01 0.83 ± 0.01 0.76
   TRZ 0.80 ± 0.03 0.83 ± 0.02 0.52
  Aliskiren DOX 0.83 ± 0.02 0.81 ± 0.02 0.68
PWT (mm)   DOX+ TRZ 0.80 ± 0.04 0.82 ± 0.02 0.82
   TRZ 0.81 ± 0.04 0.82 ± 0.02 0.82
  Perindopril DOX 0.83 ± 0.02 0.81 ± 0.02 0.58
   DOX+ TRZ 0.82 ± 0.04 0.83 ± 0.01 0.76
   TRZ 0.82 ± 0.01 0.84 ± 0.01 0.67
  Valsartan DOX 0.82 ± 0.03 0.83 ± 0.02 0.72
   DOX+ TRZ 0.84 ± 0.02 0.83 ± 0.01 0.76
  1. PWT, posterior wall thickness.
Back to article page

Cardiovascular Ultrasound

ISSN: 1476-7120

Contact us